Comparing the CFIR-ERIC matching tool recommendations to real-world strategy effectiveness data: a mixed-methods study in the Veterans Health Administration

被引:1
|
作者
Yakovchenko, Vera [1 ]
Lamorte, Carolyn [1 ]
Chinman, Matthew J. [1 ,2 ,3 ]
Goodrich, David E. [1 ]
Gibson, Sandra [1 ,4 ]
Park, Angela [5 ]
Bajaj, Jasmohan S. [6 ,7 ]
Mccurdy, Heather [8 ]
Morgan, Timothy R. [9 ,10 ]
Rogal, Shari S. [1 ,4 ,11 ]
机构
[1] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Drive C 151C. Bldg 30, Pittsburgh, PA 15240 USA
[2] VA Pittsburgh Healthcare Syst, Mental Hlth Res Educ & Clin Ctr, Pittsburgh, PA USA
[3] RAND Corp, Pittsburgh, PA USA
[4] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA
[5] Dept Vet Affairs, Off Healthcare Transformat, Washington, DC USA
[6] Cent Virginia VA Hlth Care Syst, Div Gastroenterol & Hepatol, Richmond, VA USA
[7] Virginia Commonwealth Univ, Div Gastroenterol Hepatol & Nutr, Richmond, VA USA
[8] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA
[9] VA Long Beach Healthcare Syst, Gastroenterol Sect, Long Beach, CA 90822 USA
[10] Univ Calif Irvine, Dept Med, Orange, CA USA
[11] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA
关键词
Cirrhosis; Hepatocellular carcinoma; Implementation determinants; Implementation strategies; IMPLEMENTATION;
D O I
10.1186/s13012-023-01307-x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BackgroundPractical and feasible methods for matching implementation strategies to diagnosed barriers of evidence-based interventions in real-world contexts are lacking. This evaluation compared actual implementation strategies applied with those recommended by an expert opinion-based tool to improve guideline-concordant cirrhosis care in a Veterans Health Administration national learning collaborative effort.MethodsThis convergent parallel mixed-methods study aimed to (1) identify pre-implementation Consolidated Framework for Implementation Research (CFIR) barriers to cirrhosis care through focus groups with frontline providers, (2) generate 20 recommended strategies using focus group identified barriers entered into the CFIR-Expert Recommendations for Implementing Change (ERIC) Implementation Strategy Matching Tool, (3) survey providers over two consecutive years on the actual use of 73 ERIC strategies and determine strategy effectiveness, (4) compare actual versus recommended strategy use, and (5) compare actual versus expected barriers by reverse applying the CFIR-ERIC Matching Tool.ResultsEighteen semi-structured focus groups were conducted with 197 providers representing 95 VA sites to identify barriers to quality improvement, including cirrhosis care complexity, clarity of national goals, and local leadership support. The CFIR-ERIC Matching Tool recommended strategies such as assessing for readiness and needs, promoting adaptability, building local groups, preparing champions, and working with opinion leaders and early adopters. Subsequent strategy surveys found that sites used the top 20 "recommended" strategies no more frequently than other strategies. However, 14 (70%) of the top recommended strategies were significantly positively associated with cirrhosis care compared to 48% of actual strategies. Reverse CFIR-ERIC matching found that the strategies most used in the first year corresponded to the following barriers: opinion leaders, access to knowledge and information, and resources. The strategies most frequently employed in the second year addressed barriers such as champions, cosmopolitanism, readiness for implementation, relative priority, and patient needs and resources. Strategies used in both years were those that addressed adaptability, trialability, and compatibility.ConclusionsThis study is among the first to empirically evaluate the relationship between CFIR-ERIC Matching Tool recommended strategies and actual strategy selection and effectiveness in the real world. We found closer connections between recommended strategies and strategy effectiveness compared to strategy frequency, suggesting validity of barrier identification, and application of the expert-informed tool.
引用
下载
收藏
页数:11
相关论文
共 7 条
  • [1] Comparing the CFIR-ERIC matching tool recommendations to real-world strategy effectiveness data: a mixed-methods study in the Veterans Health Administration
    Vera Yakovchenko
    Carolyn Lamorte
    Matthew J. Chinman
    David E. Goodrich
    Sandra Gibson
    Angela Park
    Jasmohan S. Bajaj
    Heather McCurdy
    Timothy R. Morgan
    Shari S. Rogal
    Implementation Science, 18
  • [2] Mortality Among Veterans with a Diagnosis of Pyruvate Kinase (PK) Deficiency: A Real-World Study Using US Veterans Health Administration Data
    Zagadailov, Erin
    Boscoe, Audra
    Garcia-Horton, Viviana
    Shi, Sherry
    Liu, Shuqian
    Shi, Lizheng
    Macaulay, Dendy
    BLOOD, 2020, 136
  • [3] Exploring unique device identifier implementation and use for real-world evidence: a mixed-methods study with NESTcc health system network collaborators
    Dhruva, Sanket S.
    Ridgeway, Jennifer L.
    Ross, Joseph S.
    Drozda Jr, Joseph P.
    Wilson, Natalia A.
    BMJ SURGERY INTERVENTIONS & HEALTH TECHNOLOGIES, 2023, 5 (01)
  • [4] What makes a sustainability tool valuable, practical and useful in real-world healthcare practice? A mixed-methods study on the development of the Long Term Success Tool in Northwest London
    Lennox, Laura
    Doyle, Cathal
    Reed, Julie E.
    Bell, Derek
    BMJ OPEN, 2017, 7 (09):
  • [5] An Empathy-Driven, Conversational Artificial Intelligence Agent (Wysa) for Digital Mental Well-Being: Real-World Data Evaluation Mixed-Methods Study
    Inkster, Becky
    Sarda, Shubhankar
    Subramanian, Vinod
    JMIR MHEALTH AND UHEALTH, 2018, 6 (11):
  • [6] COMBINING CAUSAL INFERENCE AND WITHIN-TRIAL ECONOMIC EVALUATION METHODS TO ASSESS THE COST-EFFECTIVENESS OF A MENTAL HEALTH SERVICE USING REAL-WORLD DATA: THE QUASI-EXPERIMENTAL ADAPT STUDY
    Franklin, M.
    Porter, A.
    de Vocht, F.
    Kearns, B.
    Latimer, N.
    Hernandez, M.
    Young, T.
    Kidger, J.
    VALUE IN HEALTH, 2023, 26 (12) : S87 - S87
  • [7] Comparable Overall Survival with Rituximab-Bendamustine (R-Benda) and Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) When Used As Second-Line (2L) Treatment for Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World Study Using US Veterans Health Administration Data
    Ionescu-Ittu, Raluca
    Shang, Aijing
    Velde, Nancy Vander
    Guerin, Annie
    Lin, Yilu
    Shi, Lizheng
    Shi, Sherry
    Qayum, Naseer
    BLOOD, 2018, 132